Browse OSMR

Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00041 Fibronectin type III domain
Function

Associates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events.

> Gene Ontology
 
Biological Process GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002675 positive regulation of acute inflammatory response
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0038165 oncostatin-M-mediated signaling pathway
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
Molecular Function GO:0004896 cytokine receptor activity
GO:0004924 oncostatin-M receptor activity
GO:0019838 growth factor binding
Cellular Component GO:0005900 oncostatin-M receptor complex
GO:0016324 apical plasma membrane
GO:0043235 receptor complex
GO:0045177 apical part of cell
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04151 PI3K-Akt signaling pathway
hsa04630 Jak-STAT signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-6788467: IL-6-type cytokine receptor ligand interactions
R-HSA-168256: Immune System
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between OSMR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of OSMR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of OSMR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0160.976
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8110.636
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5720.638
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.470.208
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9590.664
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1490.958
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3250.565
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1880.911
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9850.574
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2820.866
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.130.957
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4310.0136
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of OSMR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.88.26.60.452
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.810.24.60.718
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.517.6-8.10.64
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.727.3-19.60.3
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91633.3033.30.0365
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59600600.0275
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OSMR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OSMR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OSMR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OSMR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of OSMR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between OSMR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolOSMR
Nameoncostatin M receptor
Aliases OSMRB; PLCA1; IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB; interleukin-31 recepto ......
Chromosomal Location5p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting OSMR collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.